Amgen Inc. $AMGN Stock: E. Ohman J or Asset Management AB Cuts Holdings

E. Ohman J or Asset Management AB lessened its position in Amgen Inc. (NASDAQ:AMGN) by 30.7% in the 3rd quarter, Holdings Channel reports. The fund owned 13,532 shares of the medical research company’s stock after selling 5,983 shares during the period. E. Ohman J or Asset Management AB’s holdings in Amgen were worth $5,704,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of AMGN. Wellington Altus USA Inc. increased its holdings in shares of Amgen by 72.3% in the 2nd quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 34 shares during the period. Tower View Wealth Management LLC raised its position in Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 63 shares in the last quarter. Nvwm LLC lifted its stake in Amgen by 412.5% in the third quarter. Nvwm LLC now owns 82 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 66 shares during the last quarter. Security National Bank of Sioux City Iowa IA bought a new stake in Amgen in the second quarter worth $36,000. Finally, PFS Partners LLC lifted its position in shares of Amgen by 95.5% in the third quarter. PFS Partners LLC now owns 86 shares of the medical research company’s stock worth $36,000 after buying an additional 42 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Up 2.0%

Shares of AMGN opened at $447.28 on Friday. The firm has a market capitalization of $241.81 billion, a price-to-earnings ratio of 27.80, a PEG ratio of 3.21 and a beta of 0.41. Amgen Inc. has a 52 week low of $288.00 and a 52 week high of $450.98. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The business’s fifty day moving average price is $417.22 and its two-hundred day moving average price is $377.39.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. The firm had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The company’s revenue was up 9.5% on a year-over-year basis. During the same period last year, the company earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, analysts predict that Amgen Inc. will post 22.94 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were given a dividend of $2.52 per share. The ex-dividend date of this dividend was Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. Amgen’s dividend payout ratio (DPR) is currently 62.65%.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Piper Sandler maintained a Buy rating and set a $457 price target, leaving additional upside from the stock’s latest 52-week high. Piper Sandler Remains a Buy on Amgen
• Positive Sentiment: Amgen reached a new 52-week high at $447.28, roughly 55% above its October lows, highlighting strong investor momentum and demand for the stock. Amgen Reaches a New 52-Week High
• Positive Sentiment: Amgen and AstraZeneca reported Phase III Tezspire data in eosinophilic esophagitis, a potential expansion opportunity for the drug and a catalyst for the companies’ respiratory-immunology portfolios. Amgen and AstraZeneca Report Phase III Tezspire Data
• Positive Sentiment: Recent fundamentals remain supportive: Amgen’s latest reported quarter exceeded analyst expectations for both earnings and revenue, with revenue increasing year over year. Its diversified oncology, rare-disease, and inflammation portfolio also provides a steadier cash-flow profile than some high-growth biotech peers.

Insider Activity

In related news, SVP Nancy Grygiel sold 2,970 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Rachna Khosla sold 2,000 shares of Amgen stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total transaction of $825,140.00. Following the completion of the transaction, the senior vice president directly owned 6,404 shares in the company, valued at approximately $2,642,098.28. The trade was a 23.80% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 6,222 shares of company stock worth $2,540,926 in the last quarter. 0.85% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

AMGN has been the topic of a number of recent analyst reports. HSBC lowered shares of Amgen from a “buy” rating to a “hold” rating and dropped their price target for the company from $445.00 to $425.00 in a research report on Thursday, September 10th. Sanford C. Bernstein increased their price objective on Amgen from $335.00 to $345.00 and gave the company a “market perform” rating in a research report on Thursday, August 6th. Citigroup raised their price target on shares of Amgen from $345.00 to $405.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Weiss Ratings upgraded Amgen from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, October 8th. Finally, Bank of America raised their target price on Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $388.64.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.